Project Grant R01HL178865
- Federal Grant Award Summary The University of Alabama at Birmingham received a $222,750 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 21, 2025, with a completion date of June 30, 2027. The grant supports the development of a clinical decision support questionnaire designed to identify barriers to blood pressure control among adults with hypertension. This tool addresses a critical gap in...
- Federal Project Grant Award Summary The University of Alabama at Birmingham received a $1.254 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 16, 2025, with completion targeted for June 30, 2029. The award funds research to develop novel therapeutic strategies for diabetic ischemic heart failure (IHF) by improving the cardiac microenvironment. The research leverages genetic...
- Federal Project Grant Award Summary The University of Alabama at Birmingham received a $170,601 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, through July 31, 2030. This award supports the development and pilot testing of a multi-component remote care intervention designed to address the significant mortality gap in heart failure (HF) treatment outcomes between rural and urban...
- Federal Grant Award Summary The University of Alabama at Birmingham received a $162,703 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 15, 2025, with a completion date of July 31, 2030. This project focuses on implementing streamlined, standardized blood pressure (BP) measurement protocols in primary care settings. The award supports research and implementation work to develop and...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Alabama at Birmingham a $2.196 million Project Grant (CFDA 93.837: Cardiovascular Diseases Research) on August 1, 2025, for a randomized controlled clinical trial evaluating the clinical implementation of a blood pressure polygenic risk score (SBP PRS). The project, scheduled for completion by May 31, 2030, will assess whether disclosing genetic risk information derived from over 1...
- Federal Grant Award Summary The University of Alabama at Birmingham received a $745,732 Project Grant from the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), awarded May 1, 2026, with completion targeted for February 28, 2031. This research initiative, titled "Ambulatory Blood Pressure Monitoring Compared to Wrist Home Blood Pressure Monitoring in Assessing End-Organ Damage (AW-COMPARE)," will conduct a comparative clinical...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of North Carolina at Chapel Hill a $699,296 Project Grant (CFDA 93.837 – Cardiovascular Diseases Research) effective August 15, 2025 through May 31, 2029 to investigate optimal treatment algorithms and tailor therapeutic strategies for patients with chronic limb-threatening ischemia (CLTI). The research leverages data from the NHLBI-sponsored Best-CLI randomized controlled trial...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Alabama at Birmingham $186,153.00 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 16, 2025, with final completion targeted for August 31, 2030. This project grant supports research to enhance representation of pediatric patients in venous thromboembolism (VTE) clinical trials and to investigate the sociodemographic and clinical factors associated...
- Federal Grant Award Summary The University of Alabama at Birmingham received a $222,750 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, through July 31, 2027. The research deliverables focus on identifying immunogenetic risk factors associated with chronic obstructive pulmonary disease (COPD) exacerbations in African American populations. Specifically, the project...
- The University of Alabama at Birmingham (UAB) received a $158,572 Project Grant awarded September 25, 2025, from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research through August 31, 2030, focused on developing genotypic and phenotypic approaches to identify and subtype individuals with coronary heart disease (CHD), particularly those who develop CHD without prior elevated traditional risk factors....
Federal Project Grant Award Summary The University of Alabama at Birmingham (UAB) received a $735,327 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded June 22, 2026, with completion targeted for March 31, 2030. This award supports a research initiative leveraging the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study to identify individual and contextual risk factors for chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease that accounts for the majority of lower-extremity amputations in the United States. The project will examine contributors to health disparities in CLTI among community-dwelling Black and White adults across the continental United States using longitudinal cohort data enriched with detailed social determinants of health information. The deliverables include rigorous longitudinal research outputs characterizing CLTI epidemiology, risk factors, and disparity drivers through population science analysis of the REGARDS cohort (which includes 50% female participants, more than 40% Black participants, and substantial representation of Southeastern populations where peripheral artery disease risk factors are elevated). This research directly addresses a gap identified by the American Heart Association for community-based studies examining CLTI risk factors by race and social determinants of health, with findings intended to inform clinical and public health interventions to reduce amputation and disparities in this high-burden cardiovascular condition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $735.3k | 6/26/26 |